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Abstract Idiopathic hypertrophic cranial pachymeningi-
tis (IHCP) is a rare clinical entity, characterized by a
chronic inXammation causing thickening of the dura. Ade-
quate therapeutic management is still a matter of debate.
We present a patient with an IHCP, non-responsive to corti-
cotherapy. Oral methotrexate was introduced (12.5 mg
weekly) and total remission was observed after 6 weeks,
both clinically and after neuro-imaging. We conclude that
methotrexate can be eVective and a therapeutical option in
patients with IHCP who are resistant to corticotherapy or
present major side-eVects of chronic corticosteroids use.
Introduction
Hypertrophic pachymeningitis (HP) is a rare clinical entity
of diverse aetiology causing thickening of the dura. It was
Wrst described by Charcot and JoVroy regarding spinal
meninges in 1869. These early reports of hypertrophic
pachymeningitis were related to tuberculosis or syphilis [1].
NaVziger described the Wrst case of idiopathic hypertrophic
cranial pachymeningitis (IHCP) [2].
Compression of anatomic structures by the meninx,
thickened by inXammatory inWltration is the most important
cause of the clinical features. These include headache, cra-
nial nerve palsies and ataxia [3–9].
Several other causes have been recognized, including
infections, autoimmune disorders and neoplasms. When an
exhaustive evaluation fails to reveal a cause, IHCP is con-
sidered. IHCP is a very rare disorder that aVects predomini-
nantly male patients. Adequate therapeutic management is
still a matter of debate. Several therapeutic strategies have
been proposed, including steroids and other immunosup-
pressive agents, as well as radiotherapy and surgical
removal of the aVected tissue [10].
In this case report, we present a patient with an IHCP
and his responsiveness to oral methotrexate.
Case report
A 62-year-old male consulted in 2002 about a bi-temporal,
non-throbbing headache, jaw claudication and diVuse
articular pains. He described episodes of transitory hemia-
nopsia. Neurological examination showed no signs of
focalisation. He had no history of clinical signs or symp-
toms of systemic collagen vascular disease, syphilis, tuber-
culosis or obvious metastatic cancer. Laboratory test
showed an erythrocyte sedimentation rate (ESR) of 91 mm
and a C-reactive protein of 104 mg l¡1 (normal <
3.2 mg l¡1). Brain MRI study and biopsies of both temporal
arteries were negative. After introduction of oral cortico-
therapy (prednisone 1 mg kg¡1 day¡1) an immediate (less
than 24 h) and total remission was observed. His neurologist
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concluded the disease as a giant cell arteritis. In the follow-
ing years, multiple attempts were made by his physician to
reduce his corticotherapy. With daily doses of less than
30 mg the headache and the inXammatory syndrome reap-
peared.
A few months before his admission to our hospital the
patient presented with recurring headaches, diVerent from
the headaches of 2002. He described intense occipital, non-
throbbing headaches and cervical pain. The inXammatory
syndrome worsened (ESR 100 mm). This exacerbation was
accompanied by a lingual hypoesthesia and an important
photophobia. Attempts to control this aggravation by inten-
sifying his corticotherapy (80 mg daily) were unsuccessful.
He was admitted in our hospital in November 2005. At
this time neurological examination showed a 4th, 5th and
12th left cranial nerve paresis and paresthesia of the left
leg. The rest of the clinical examination was normal.
Opthalmologic examination showed glaucoma as a compli-
cation of his chronic corticotherapy. Blood analysis
revealed an ESR of 60 mm and a C-reactive protein level of
55 mg l¡1. Brain MRI revealed a diVuse thickening and
enhancement of the pachymeninges along both sides of the
tentorium (Fig. 1).
All known causes of pachymeningitis were explored.
Blood analyses of rheumatoid factor, complement activa-
tion, antineutrophilic cytoplasmic antibodies (ANCA), anti-
nuclear antibodies and tumour markers were normal.
Cerebrospinal Xuid (CSF) analyses revealed discrete pleio-
cytosis (white blood cell count 23 mm¡3 and elevated pro-
tein levels 1.33 g l¡1, normal value 0.6–1 g l¡1) but the
virologic, parasitologic and bacteriologic analyses were neg-
ative. PCR assay for the detection of Mycobacterium tuber-
culosis DNA was negative. Carcinomatous cells were not
detected in two CSF samples. Angiotensin converting
enzyme was slightly elevated (2.2 UI L¡1, interval 0.5–
1.50). Chest CT and MRI, bronchial Wbroscopy with biopsy,
gallium scintigraphy, neurophysiologic explorations pre-
sented no arguments for a systemic disease. Investigation for
a neoplasia (tumour markers, chest and abdominal CT and
bone scintigraphy) was negative. C-reactive protein contin-
ued to rise (115 mg L¡1) and a signiWcant worsening of the
patient’s general condition was noted with a weight loss of
8 kg in 3 months. A control MRI study conWrmed the wors-
ening of the diVuse thickening of the dura (Fig. 2).
A meningeal biopsy was performed which showed an
inXammatory inWltration, locally granulomatous but non-
speciWc. No signs of vasculitis, neoplastic cells or infec-
tious agents were found.
With these exhaustive clinical and para-clinical investi-
gations being negative, we concluded at an IHCP. At that
moment the patient was still treated with 60 mg of predni-
sone daily.
Because of his resistance to chronic steroid therapy, IV
methylprednisone was administered (1 g day¡1 for 3 days)
and oral methotrexate 12.5 mg weekly was started. Total
remission of the clinical and biologic abnormalities was
evident 6 weeks after introduction of methotrexate as long
as there was a progressive reduction of corticotherapy. He
regained 7 kg in the following weeks. No side eVects were
noted. A control MRI study, performed 6 weeks after intro-
duction of methotrexate, demonstrated a practically total
abolition of the dural enhancement (Fig. 3).
Currently, after 10 months of follow-up (after introduc-
tion of methotrexate), the patient is doing well and his cor-
ticotherapy is continually reduced. He recovered for his
glaucoma and had no side eVects for methotrexate. He cur-
rently takes 15 mg of oral methotrexate weekly and
12.5 mg cortisone daily and continues to reduce his cortico-
therapy. ESR and C-reactive protein remain normal. How-
ever he continues to describe facial paresthesias. Our
therapeutic strategy is to lower the cortisone dosage until
10 mg daily and after a stable condition (clinically and
Fig. 1 Axial (a) and coronal (b) 
T1-weighted contrast-enhanced 
MR images show markedly 
thickened and enhanced dura 
extending from the vertex to the 
tentoriumRheumatol Int (2008) 28:713–718 715
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biologically) of minimum 6 months, we will try to lower
the methotrexate dosage.
Discussion
Our patient presented with IHCP, which was conWrmed by
neuroimaging and biopsy, and which improved with the
association of corticosteroids and methotrexate. Since the
introduction of CT and MRI, IHCP has been increasingly
reported in recent literature. The clinical picture can be
heterogeneous. Parney et al. [11] described headache, cranial
nerve palsy and ataxia in 88, 62 and 32% of the cases,
respectively. Cranial nerve palsies are due to compression
of the exit zone of the nerve roots by the hypertrophic
basal pachymeningitis. Riku and kato [12]  described two
patterns of the multiple cranial neuropathies depending on
the site of dural inXammation: cavernous sinus to superior
orbital Wssure involvement and falcotentorial to posterior
fossa dural involvement. The headache is probably related
to the dural inXammation because in many cases no evi-
dence of raised intracranial pressure was present. Recently,
the headache proWle was described by Wang et al. [13] and
characterized as a chronic daily headache, often resembling
chronic migraine. Our patient also described daily head-
ache, but the headache did not resemble chronic migraine.
Rarely, IHCP has been reported to lead to internal carotid
artery occlusion, venous sinus occlusion and obstructive
hydrocephalus [14–18].
Hypertrophic pachymeningitis can be divided into two
types: secondary, in which there is an identiWable coexis-
ting cause and idiopathic, in which no identiWable cause, as
Fig. 2 Axial (a) and coronal (b) 
T1-weighted contrast-enhanced 
MR images show progression of 
dural thickening corresponding 
with the clinical worsening at the 
time of the biopsy
Fig. 3 Axial (a) and coronal (b) 
T1-weighted contrast-enhanced 
MR images obtained 6 weeks af-
ter introduction of methotrexate 
show regression of dural thick-
ening and enhancement716 Rheumatol Int (2008) 28:713–718
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in our patient. IHCP is thus a diagnosis of exclusion. DiVeren-
tial diagnoses are extensive. In our case, we performed a
diagnostic work-up based on all known causes in current
literature [10]. Most authors consider intracranial hypoten-
sion, infections, systemic autoimmune disorders, malig-
nancy and meningioma as the main aetiologies of enhanced
dura mater on gadolinium MRI.
Although by deWnition no cause is found for IHCP,
diVerent abnormalities are described. In a series of 12
patients, Kupersmith et al. described an elevated ESR in
41%. The chemistry of CSF was variable and non-diagnos-
tic, but protein was elevated in 50% of their patients. They
recommend biopsy of the dura when the patient clinically
deteriorates or the neuro-imaging worsens, despite treat-
ment [10]. Until now the pathogenesis of IHCP remains
unclear. The close relationship to autoimmune disorders
such as Wegner’s granulomatosis, rheumatoid arthritis or
other connective tissue diseases has been described.
Recently p-ANCA positive HP has been reported. As
p-ANCA antibodies have been detected in many vasculiti-
des, microvasculitis may be involved in some cases of
IHCP [19].
Neuroimaging plays a key role in the evaluation of
IHCP. Nevertheless, image study of IHCP can remain neg-
ative for 2 years before there is any signiWcant  Wnding
[20]. The MR images show a diVusely thickened dura, usu-
ally isointense on T1-weighted slices that enhances
strongly after paramagnetic contrast injection due to an
inXammatory reaction of the pachymeninges. On T2-
weighted imaging, the dura appears commonly hyperin-
tense, rarely hypointense related to Wbrosis process. The
use of gadolinium is important for the evaluation of the
pattern of meningeal enhancement that may diVerentiate
between pachy- and lepto-meningitis. MRI can also dem-
onstrate areas suitable for biopsy. In our case, the MRI was
normal in the beginning. Although there was an evident
change in symptomatology of disease progression, the
possibility remains that the symptoms diagnosed as a giant
cell arteritis in 2002 was the initial presentation of an
occult IHCP.
As mentioned above, the role of the dural biopsy is
important in the diagnostic process but even more impor-
tant is to exclude other causes of HP. Taken into account
the high number of relapses reported in literature, biopsy in
an early disease stage must be discussed. Non-speciWc
inXammatory changes in the dura are common histopatho-
logic features. Vasculitis or granulomatous changes have
been described as well [19].
In our case report angiotensin converting enzyme levels
in CSF were elevated and although no other argument was
found, neurosarcoidosis must be discussed in our patient.
Although the biopsy performed in our patient did not Wnd
elements in favour of neurosarcoidosis, we must admit that
chronic immunosuppressive therapy can mask the results.
In recent literature there is no consensus on the adequate
management of IHCP. Spontaneous resolution of both clini-
cal symptoms and signs, and dural thickening has been
reported [21]. A variety of therapeutic approaches have
been tried alone or in combination. Corticosteroid therapy
is often eVective in ameliorating the symptoms and signs,
and in stopping the disease progression [22]. In those who
do not respond to steroids or those who develop steroid
dependence, other immunosuppressive therapies have been
used [23].
Most authors agree that corticotherapy should be the
Wrst approach in IHCP. Some authors describe only a par-
tial eVectiveness of corticosteroid therapy, with partial
clinical improvement and relapse when tapering the dos-
age [10]. Table 1 gives an overview of the therapeutic tri-
als since 1990. Searching the pubmed database in the
English-language literature for patients with IHCP receiving
treatment, we identiWed a total of 60 patients. The most
frequently used treatment was steroid therapy (n = 56,
93%). Thirty-nine patients were treated with corticoste-
roids as monotherapy (65%). In this subgroup,18 patients
experienced relapses (46%). DiVerent add-on therapeutic
options are proposed; six patients received azathioprine,
one patient cyclophosphamide, one patient underwent sur-
gery and two patients were treated with methotrexate. In
all these patients receiving add-on therapy, a sustained
remission was described, permitting to stop or reduce the
daily dose of corticosteroids. Considering occult tubercu-
losis, one patient was empirically treated with antitubercu-
lar medication as monotherapy. Surgical excision is
sometimes necessary for patients with mass eVect due to
thickening of the skull base [19]. Symptomatic hydrocepha-
lus sometimes requires ventriculoperitoneal shunting. In
the identiWed patient group, Wve were operated, one after
therapeutic failure of the corticotherapy. Recently the use
of low-dose pulse subcutaneous methotrexate was pro-
posed as monotherapy. Total remission of the clinical and
neuro-imaging abnormalities was evident after 6 months
[24–32].
In our patient we chose a low-pulse oral methotrexate
scheme of 12.5 mg weekly. Although, large randomized tri-
als are required to prove the eYcacy and tolerability of
methotrexate at diVerent doses and routes of administration,
we noted a spectacular improvement within the 6 weeks
following introduction of methotrexate. After introduction
of methotrexate we were able to taper the corticotherapy
and reduce the side-eVects of its chronic use (glaucoma).
There is no consensus about the duration of this therapy.
After minimum 12 months we will try to stop the metho-
trexate.Rheumatol Int (2008) 28:713–718 717
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Conclusion
In this patient with an IHCP, methotrexate was a safe and
eVective treatment, resulting in a total remission after
6 weeks and allowing to reduce corticotherapy. In patients
with IHCP which is non-responsive to corticotherapy, or
in patients who present major side-eVects of their chronic
use of corticosteroids, methotrexate seems indicated.
However further work is required to determine the place
of oral methotrexate in the therapeutic management of
IHCP.
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